Advanced BioNutrition Corp.

Nutritional products to promote health and control disease in the fields of aquaculture and terrestrial agriculture

Advanced BioNutrition Corp. (ABN) was formed in 2001 by Dr. David J. Kyle. In 2001 ABN has raised $2.5 million in Series A funding and a year later Sherbrooke Capital invested $1.0 million in ABN, co-leading a total equity financing of $3.6 million with Eastbourne Capital Management, L.L.C. The round also included investments by the State of Maryland Department of Business and Economic Development and individuals. ABN has completed series A financing with $2.5 million investment in 2003. ABN has entered into collaborative research and development projects with the California State University Hayward (CSUH) and the San Diego State University (SDSU).

William F. Kirk, CEO

Ignacio Aranguren T.
Dr. Charles J. Arntzen
Jim Carruthers, Jr.
John K. Giannuzzi
Keith Gillard
William F. Kirk
David J. Kyle
Walter Locher

Charles J. Arntzen, Ph.D.
Roger Clemens, Ph.D.
Colin Ratledge, Ph.D.
Donald Lightner, Ph.D.

7155 Columbia Gateway Drive
Columbia, MD 21046
USA
Phone: +1-410-730-8600
Fax: +1-410-730-9311

The company has a large portfolio of products and technologies that impact animal health and human nutrition. These include, for example: Currently ABN is developing a novel platform technology for oral vaccines to combat fish diseases (Saltonstall-Kennedy grant), as well as a crustacean expression system of glycosolated recombinant proteins in mass production as an alternative to mammalian and insect cell culture systems. The company’s microencapsulation technology, which is currently in development, allows the targeted delivery of viable probionts through the stomach and directly to the hind-gut of aquatic animals to improve disease resistance. In addition, ABN offers algal sources of essential fatty acids (DHA, ARA) in specialty feeds (e.g., AquaGrow) to provide enhanced health and nutritional benefits for farm animals. The company’s products contain astaxanthin, a pigment found in the natural diets of fish, which increases the immune systems of aquatic livestock.

cytotoxic chemotherapy (clincial trial)
Bone Marrow Cells - Osteoporosis (clinical trial)
Apheresis Reduction - Lymphoma (clinical trial)
Apheresis Reduction - Breast Cancer (clinical trial)

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.